Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Pharmacokinetics/Pharmacodynamics Analysis of Veterinary Antimicrobial Agents
share announcement

Pharmacokinetics/Pharmacodynamics Analysis of Veterinary Antimicrobial Agents

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics of Drugs".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 3748

Special Issue Editor

Prof. Dr. Lingli Huang

E-Mail Website
Guest Editor
National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, China
Interests: veterinary pharmacokinetics; veterinary drug residues; food safety

Special Issue Information

Dear Colleagues,

Irrational use of antimicrobial drugs in animals may result in the development and spread of bacterial resistance, which threatens human and animal health. The pharmacokinetic/pharmacodynamic (PK/PD) model can link pharmacokinetics and pharmacodynamics to evaluate and predict dose–concentration–response relationships. PK/PD model is an effective way of optimizing the dosage regimen to guide clinical use and prevent the emergence of resistance. The PK/PD model has been applied in veterinary antimicrobial drugs for two decades, playing a vital role in the rational use of antimicrobial drugs. This Special Edition on One Health between human and animals focuses on the PK/PD model in veterinary antimicrobial drugs in primary care and will consist of 10–15 manuscripts, which may include original research, review articles, case series, and opinion papers. We are interested in both qualitative and quantitative research across the following areas:

  1. Application of the PK/PD model in the research and development of new drugs (e.g., preclinical PK/PD, translational PK/PD);
  2. Optimization of dosage regimen through the PK/PD model (e.g., PK/PD parameters, combination);
  3. Establishment of clinical breakpoint and PK/PD cutoff;
  4. Prevention and treatment of drug-resistant bacteria (e.g., HFIM,MSW).

Prof. Dr. Lingli Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 4586 KiB  
Article
ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance
by Min Chen, Yujuan Yang, Yupeng Ying, Jiamin Huang, Mengyuan Sun, Mian Hong, Haizhen Wang, Shuyu Xie and Dongmei Chen
Antibiotics 2023, 12(2), 403; https://doi.org/10.3390/antibiotics12020403 - 17 Feb 2023
Cited by 1 | Viewed by 1666
Abstract
Enrofloxacin (ENR) is one of the most common drugs used in poultry production to treat bacterial diseases, and there is a high risk of drug interactions (DDIs) between polyether anticoccidial drugs added to poultry feed over time. This may affect the efficacy of [...] Read more.
Enrofloxacin (ENR) is one of the most common drugs used in poultry production to treat bacterial diseases, and there is a high risk of drug interactions (DDIs) between polyether anticoccidial drugs added to poultry feed over time. This may affect the efficacy of antibiotics or lead to toxicity, posing a potential risk to the environment and food safety. This study aimed to investigate the DDI of ENR and salinomycin (SAL) in broilers and the mechanism of their DDI. We found that SAL increased the area under the curve and elimination half-life of ENR and ciprofloxacin (CIP) by 1.3 and 2.4 times, 1.2 and 2.5 times, respectively. Cytochrome 3A4 (CYP3A4), p-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) were important factors for the DDI between ENR and SAL in broilers. ENR and SAL are substrates of CYP3A4, P-gp and BCRP in broilers; ENR and SAL inhibited the expression of CYP3A4 activity in a time- and concentration-dependent. Meanwhile, ENR downregulated the expression of P-gp and BCRP in a time- and concentration-dependent manner. A single oral administration of SAL inhibited CYP3A4, P-gp, and BCRP, but long-term mixed feeding upregulated the expression of CYP3A4, P-gp, and BCRP. Molecular docking revealed that ENR and SAL compete with each other for CYP3A4 to affect hepatic metabolism, and compete with ATP for P-gp and BCRP binding sites to inhibit efflux. ENR and SAL in broilers can lead to severe DDI. Drug residues and resistance following co-administration of ENR and SAL and other SAL-based drug-feed interactions warrant further study. Full article
(This article belongs to the Special Issue Pharmacokinetics/Pharmacodynamics Analysis of Veterinary Antimicrobial Agents)
►▼ Show Figures

Graphical abstract

11 pages, 1654 KiB  
Article
Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction
by Mei Li, Ziyong Xu, Wang Lu, Liping Wang and Yujuan Zhang
Antibiotics 2022, 11(8), 1005; https://doi.org/10.3390/antibiotics11081005 - 26 Jul 2022
Cited by 2 | Viewed by 1373
Abstract
Studies on pharmacokinetic drug–drug interactions have highlighted the importance of P-glycoprotein (P-gp) because of its involvement in substrate drug transport. This study aimed to investigate the role of chicken xenobiotic receptor (CXR) in the regulation of P-gp and its influences on pharmacokinetics of [...] Read more.
Studies on pharmacokinetic drug–drug interactions have highlighted the importance of P-glycoprotein (P-gp) because of its involvement in substrate drug transport. This study aimed to investigate the role of chicken xenobiotic receptor (CXR) in the regulation of P-gp and its influences on pharmacokinetics of P-gp substrate sulfadiazine. ALAS1 and CYP2C45, the prototypical target genes of CXR, were used as a positive indicator for CXR activation in this study. Results show that ABCB1 gene expression was upregulated, and transporter activity was increased when exposed to the CXR activator metyrapone. Using ectopic expression techniques and RNA interference to manipulate the cellular CXR status, we confirmed that ABCB1 gene regulation depends on CXR. In vivo experiments showed that metyrapone induced ABCB1 in the liver, kidney, duodenum, jejunum and ileum of chickens. In addition, metyrapone significantly changed the pharmacokinetic behavior of orally administered sulfadiazine, with a Cmax (8.01 vs. 9.61 μg/mL, p < 0.05) and AUC0-t (31.46 vs. 45.59 h·mg/L, p < 0.01), as well as a higher T1/2λ (2.42 vs.1.67 h, p < 0.05), Cl/F (0.62 vs. 0.43 L/h/kg, p < 0.01) and Vz/F (2.16 vs.1.03 L/kg, p < 0.01). Together, our data suggest that CXR is involved in the regulation of P-gp, and, consequently, the CXR activator can affect, at least in part, the pharmacokinetic behavior of orally administered sulfadiazine. Full article
(This article belongs to the Special Issue Pharmacokinetics/Pharmacodynamics Analysis of Veterinary Antimicrobial Agents)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop